Forward step by step with Action Plan 2016 - Continued revenue growth - Significant pipeline progress


Hamburg, Germany - 26 March 2013: Evotec AG (Prime Standard Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the fiscal year ended 31 December 2012.
Growth trend continues                                                    
- Revenues +9% to EUR 87.3 m                                              
- Operating result adjusted EUR 1.4 m; net income EUR 2.5 m               
- Operating cash flow +18% to EUR 12.0 m                                  
- Strong and stable liquidity position of EUR 64.2 m                      
- Expected revenues of EUR 90 m to EUR 100 m in 2013  
Strong progress in all business units (EVT Execute/Integrate/Innovate achieved                                                                  
- Multiple new alliances and contract extensions (e.g. Bayer, CHDI and NIH)
- Acceleration of EVT Innovate strategy through alliances with Harvard and Yale                                                                      
- Multiple milestones achieved with e.g. Andromeda/Teva, Boehringer Ingelheim, MedImmune, Novartis and Ono                                    
- Strategic alliance with 4-Antibody                                      
- Acquisition of CCS Cell Culture Service GmbH (after period-end)
Significant short- and mid-term pipeline catalysts                        
- DiaPep277, positive Phase III results confirmed, data of second pivotal trial to come end of 2014                                         
- Large Phase IIb trial started with EVT302 in Alzheimer's Disease        
- Multiple clinical trials expected to start and read out in 2013/2014 (e.g. Phase II with EVT100 series in depression, several Phase I programmes in oncology, pain and other indications)
1. Operational performance - Good revenue growth, Milestones drive profitability
Revenue growth of 9%, operating result, R&D investments and liquidity in line with adjusted guidance                              
Evotec achieved continued profitable growth in 2012 with revenues up 9% to EUR 87.3 m (2011: EUR 80.1 m) and a net income of EUR 2.5 m (2011: EUR 6.7 m). The shift in revenues from milestones from Q4 2012 into 2013 had a negative effect on profitability, which as a result was lower than originally guided. Growth in revenues was driven by the increase in revenues within the Company's drug discovery alliances and significant milestone payments through its collaborations in the amount of EUR 12.3 m (2011: EUR 10.5 m).
The gross margin of the Group decreased to 35.6% (2011: 43.7%). The margin difference compared to 2011 is mainly attributable to a decrease in upfront payments, the ramp-up of capacities in EVT Execute, lower margin compound  management revenues and the move into the new Manfred Eigen Campus at the start of 2012.                                                            
Evotec's operating result for 2012 amounted to EUR (3.2) m (2011: EUR 5.2 m), which primarily was due to a lower gross profit and an impairment of intangible assets in the amount of EUR 3.5 m (2011: EUR 0.6 m net of reversal of impairment). The impairment was mainly the result of the termination of the VR1 partnership with Pfizer. The operating result before impairment and changes in contingent consideration was positive at EUR 1.4 m (2011: EUR 5.8 m). Net income amounted to EUR 2.5 m (2011: EUR 6.7 m). The improvement of the net income over the operating result primarily resulted from deferred tax income amounting to EUR 8.3 m (2011: EUR 2.5 m).
R&D expenditure amounted to EUR 8.3 m (2011: EUR 8.4 m). Evotec's unfunded research focused on selected discovery projects in the key areas of CNS, oncology, inflammation, metabolic and kidney disease such as the CureBeta and CureNephron alliances with Harvard University.                        
Although there were significant investments in capital expenditures of EUR 8.2 m (2011: EUR 8.1 m) as well as in intangible assets and earn-out payments, the Company's liquidity position increased to EUR 64.2 m (2011: EUR 62.4 m), this is composed of cash and cash equivalents (EUR 39.1 m) and of investments (EUR 25.1 m). Therefore Evotec is very well-financed.      
2. Evotec Action Plan 2016 - Step by step forward for higher Innovation Efficiency                                                                
Update on discovery alliances, development partnerships and status of pre-clinical programmes    
Action Plan 2016 - Innovation Efficiency is the strategy framework that was initiated in March 2012. EVT Execute aims to deliver cost efficient and industrialised services for drug discovery on a fee-for-service basis. EVT Integrate is the systematic approach to progress targets through the pre-clinic, on a research payments, milestones and royalties success basis. EVT Innovate involves accelerating promising drug discovery ideas and assets to partnerships with upfront payments, premium research fees, milestones and royalties.                                                                
EVT Execute - Continued trend towards outsourcing services for biotech and Pharma; important new and extended collaborations                         
With CHDI, a privately funded not-for-profit research organisation dedicated to developing therapies for Huntington's disease (HD), Evotec extended its collaboration until the end of 2015. This contract extension could be worth up to $ 41 m in research payments for Evotec.
With the United States Environmental Protection Agency (EPA) Evotec entered into a multi-year compound management agreement. The contract covers a period of five years and has a total value of up to EUR 7.7 m (approximately $ 10 m).
With the National Institutes of Health (NIH) Evotec signed a multi-year agreement for the operation of a small molecule repository (SMR). The contract is funded in its entirety by NIH, covers a period of up to 10 years and has a total estimated value of up to EUR 60 m (approximately $ 75 m).
With 4-Antibody Evotec acquired access to a fully integrated antibody discovery and development service. Evotec's novel and unique high throughput and high content screening approach coupled with 4-Antibody's high throughput antibody selection approach will allow screening of large and diverse antibody populations for desired functionality and activity at a much earlier stage of selection. This unique combined approach is expected to substantially reduce attrition rates at later development stages.
Signed in December 2012 and effective 01 January 2013, Evotec acquired Cell Culture Service GmbH (CCS), a Hamburg-based company which supports the cell culture needs of a world-wide customer base of biotech and pharmaceutical companies. CCS is one of the leading suppliers of custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes and proteins for high throughput screening with more than 10 years experience in bulk cell production.     
EVT Integrate - New strategic multi-target alliance with Bayer and several key milestone achievements                                                
With Bayer Evotec entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis. Evotec received EUR 12 m as an upfront payment. In total, Evotec could receive pre-clinical, clinical and sales milestones of up to EUR 580 m plus royalties. Under the terms of the deal both parties  contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of candidates in endometriosis.                 
The progress and success of existing core alliances was significant. Milestones were achieved within the alliances with Boehringer Ingelheim, Ono and Novartis. In 2012 Evotec was able to secure multiple pre-clinical milestones totalling EUR 12.3 m.                                           

EVT Innovate - Significant clinical outcomes ahead, Cure X initiative driven by Harvard and Yale
The first Phase III trial on DiaPep277 demonstrated the achievement of both its primary and secondary endpoints. Moreover it was announced that the recruitment of the second Phase III trial was closed in September 2012. Results of this second pivotal trial are expected towards the end of 2014.
Roche started a substantial Phase II trial with EVT302 at the end of 2012 aiming at recruiting 450 patients in more than 120 centres worldwide to assess the efficacy and safety of this compound in patients with moderate severity Alzheimer's disease (AD). This clinical trial is one of the very few late-stage trials in this AD patient population. Results are expected during the second half of 2015.                                           
Evotec entered into a license agreement with Janssen for its NR2B subtype selective NMDA-antagonist portfolio for development against diseases in the field of depression. Evotec received an upfront payment of $ 2 m with an additional $ 6 m to be paid upon confirmation of certain pre-clinical properties of the candidates. Evotec could receive up to $ 67 m for the first product depending on certain clinical, regulatory and launch events, as well as additional milestone payments upon successful completion of certain events for additional indications and/or compounds. Evotec could be entitled to an additional $ 100 m in commercial milestones depending on meeting certain sales thresholds and royalties which could be as high as double-digit on certain future sales of royalty bearing products. It is the Company's expectation that Janssen will initiate Phase II clinical trials in depression during the course of 2013/14.
With Janssen, Evotec also announced the licensing of a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. The agreement between Evotec and Janssen triggered an upfront payment of $ 8 m. Upon achievement of certain pre-clinical, clinical, regulatory and commercial goals, Evotec could receive milestone payments of up to $ 300 m per product. In addition, Janssen will pay royalties on future sales of any products that result from this collaboration.                                                            
Evotec achieved key milestones within its product development alliance with MedImmune in the field of beta cell regeneration and received two milestone payments totalling EUR 1 m. EVT770 is currently in pre-clinical development and could enter trials within 24 months.                                  
In addition Evotec signed two co-development agreements with Haplogen and Apeiron. With Haplogen Evotec aims to discover and develop small molecules against viral infectious diseases and with Apeiron the objective of developing immunomodulatory lead compounds for the treatment of cancer.   
After the success of CureBeta with Harvard University, Evotec and Harvard started their second strategic alliance, including Brigham and Women's Hospital and the University of Southern California aimed at discovering and developing new biomarkers and treatments in the field of kidney disease. This programme CureNephron is designed to deliver and exploit novel therapeutic targets as well as biomarkers that allow more accurate diagnosis, monitoring and treatment of chronic and acute kidney disease.  
An open innovation alliance was formed with Yale University. Under the agreement, Evotec and Yale intend to leverage first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need ready for partnering.                                  
Two product development collaborations were terminated during the course of 2012. The EVT401 agreement in animal health and the VR1 collaboration with Pfizer ended, because of strategic portfolio reviews pursued by the respective partners.                                                      
3. Guidance 2013                                                          
In 2013, total Group revenues are expected to grow to a level between EUR 90 m to EUR 100 m. This assumption is based on the current order book, expected new contracts and contract extensions and most importantly on the achievement of certain milestone payments.                                
Evotec expects research and development (R&D) expenses in 2013 to increase above the levels of 2012. This is primarily due to additional investments in the strategic Cure X franchise primarily in the fields of metabolic diseases and regenerative medicine. In total, R&D expenditure is expected to be around EUR 10 m in 2013.
On that basis Evotec's Group operating result before impairment and changes in contingent consideration, if any, for the year 2013 is expected to improve over 2012. The Company expects to maintain its liquidity above EUR 60 m at the end of 2013, excluding any potential cash outflow for M&A transactions and related payments.                                        
Webcast/Conference Call                                                 
Evotec will broadcast its press & analyst conference in Frankfurt live on the internet. The Management Board will inform you about the FY 2012 results as well as update you on the status of 'Action Plan 2016 - Innovation Efficiency in Drug Discovery' and present an outlook for the fiscal year 2013.
Date: Tuesday, 26 March 2013                                              
Time: 9.00 am CET (08.00 am GMT/04.00 am EDT)                             
To join the audio webcast and to access the presentation slides you will find a link on our home page shortly before the event.     
For those who prefer to listen to the presentation via phone, please dial:
From Germany:    +49(0)69 20 17 44 210                                      
From UK:            +44 207 153 9154                                                
From USA:          +1 877 423 0830                                                 
Access Code:       638618#                                                      
The on-demand version of the webcast will be available on our website: > Investors > Events > Financial Calendar.    
Fiscal Year 2012 Results
Key figures of consolidated income statement
Evotec AG and subsidiaries
In T€ except share data and per share data

January to  December

January to  December

Change in %


Gross margin in %

Research and development expenses

Selling, general and administrative expenses

Amortisation of intangible assets

Impairment of intangible assets

Reversal of impairment of intangible assets

Other operating income

Other operating expenses

Operating income (expense)

Operating income*

Net income

Weighted average shares outstanding

Net income per share (basic and diluted)

* Excluding impairments and reversal of impairments and changes in contingent considerations
Key figures of consolidated statement of financial position
Evotec AG and subsidiaries
In T€

31 Dec 2012
31 Dec 2011
Change in %

Cash, cash equivalents and investments

Working capital

Current and non-current loans and finance lease obligations

Stockholders' equity

Total assets

Contact Evotec AG: Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.